Filter Results:
(176)
Show Results For
- All HBS Web
(176)
- People (1)
- News (51)
- Research (84)
- Events (3)
- Multimedia (8)
- Faculty Publications (52)
Show Results For
- All HBS Web
(176)
- People (1)
- News (51)
- Research (84)
- Events (3)
- Multimedia (8)
- Faculty Publications (52)
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is... View Details
Keywords: Digital Technologies; Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Information Technology; Technology Adoption; Biotechnology Industry; Pharmaceutical Industry; United States; California; Puerto Rico; Rhode Island
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
- Article
Comparative Costs of Advanced Proton and Photon Radiation Therapies: Lessons from Time-driven Activity-based Costing in Head and Neck Cancer
By: Nikhil G. Thaker, Steven J. Frank and Thomas W. Feeley
Time-driven activity-based costing (TDABC) is an innovative costing tool in healthcare that can be used to directly compare the true cost of competing technologies over the full care cycle. Rather than only comparing therapeutic effectiveness over a limited number of... View Details
Keywords: Head And Neck Cancer; IMRT; Proton Therapy; Time-Driven ABC; Information Technology; Activity Based Costing and Management; Medical Specialties
Thaker, Nikhil G., Steven J. Frank, and Thomas W. Feeley. "Comparative Costs of Advanced Proton and Photon Radiation Therapies: Lessons from Time-driven Activity-based Costing in Head and Neck Cancer." Journal of Comparative Effectiveness Research 4, no. 4 (2015): 297–301.
- November 2022 (Revised March 2024)
- Case
Replika AI: Monetizing a Chatbot
By: Julian De Freitas and Nicole Tempest Keller
In early 2018, Eugenia Kuyda, co-founder and CEO of San Francisco-based chatbot Replika AI, was deciding how to monetize the app she had built. Launched in 2017, Replika was a consumer AI “companion app” developed by a team of AI software engineers originally based in... View Details
Keywords: Mental Health; Subscriber Models; TAM; Monetization Strategy; Marketing Strategy; Product Marketing; AI and Machine Learning; Applications and Software; Product Positioning; Health Disorders; Technology Industry
De Freitas, Julian, and Nicole Tempest Keller. "Replika AI: Monetizing a Chatbot." Harvard Business School Case 523-016, November 2022. (Revised March 2024.)
- May 2017
- Other Article
Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis
By: Andrew Hill, Po-Ru Loh, Ragu B. Bharadwaj, Pascal Pons, Jingbo Shang, Eva C. Guinan, Karim R. Lakhani, Iain Kilty and Scott Jelinsky
BACKGROUND:
The association of differing genotypes with disease-related phenotypic traits offers great potential to both help identify new therapeutic targets and support stratification of patients who would gain the greatest benefit from specific drug classes.... View Details
Keywords: Crowdsourcing; Genome-wide Association Study; Logistic Regression; Open Innovation; PLINK; Collaborative Innovation and Invention
Hill, Andrew, Po-Ru Loh, Ragu B. Bharadwaj, Pascal Pons, Jingbo Shang, Eva C. Guinan, Karim R. Lakhani, Iain Kilty, and Scott Jelinsky. "Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis." GigaScience 6, no. 5 (May 2017).
- January 2016 (Revised January 2019)
- Case
The Allergan Board Under Fire (A)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R＆D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Management Teams; Business and Shareholder Relations; Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (A)." Harvard Business School Case 316-010, January 2016. (Revised January 2019.)
- October 2019
- Article
Adaptive Platform Trials: Definition, Design, Conduct and Reporting Considerations
By: Derek C. Angus, Brian M. Alexander, Scott Berry, Meredith Buxton, Roger Lewis, Melissa Paoloni, Steven A. R. Webb, Steven Arnold, Anna Barker, Donald A. Berry, Marc J. M. Bonten, Mary Brophy, Christopher Butler, Timothy F. Cloughesy, Lennie P. G. Derde, Laura J. Esserman, Ryan Ferguson, Louis Fiore, Sarah C. Gaffey, J. Michael Gaziano, Kathy Giusti, Herman Goossens, Stephane Heritier, Bradley Hyman, Michael Krams, Kay Larholt, Lisa M. LaVange, Philip Lavori, Andrew W. Lo, Alexander J. London, Victoria Manax, Colin McArthur, Genevieve O’Neill, Giovanni Parmigiani, Jane Perlmutter, Elizabeth A. Petzold, Craig Ritchie, Kathryn M. Rowan, Christopher W. Seymour, Nathan I. Shapiro, Diane M. Simeone, Bradley Smith, Bradley Spellberg, Ariel Dora Stern, Lorenzo Trippa, Mark Trusheim, Kert Viele, Patrick Y. Wen and Janet Woodcock
Researchers, clinicians, policymakers, and patients are increasingly interested in questions about therapeutic interventions that are difficult or costly to answer with traditional, free-standing, parallel-group randomized controlled trials (RCTs). Examples include... View Details
Angus, Derek C., Brian M. Alexander, Scott Berry, Meredith Buxton, Roger Lewis, Melissa Paoloni, Steven A. R. Webb, Steven Arnold, Anna Barker, Donald A. Berry, Marc J. M. Bonten, Mary Brophy, Christopher Butler, Timothy F. Cloughesy, Lennie P. G. Derde, Laura J. Esserman, Ryan Ferguson, Louis Fiore, Sarah C. Gaffey, J. Michael Gaziano, Kathy Giusti, Herman Goossens, Stephane Heritier, Bradley Hyman, Michael Krams, Kay Larholt, Lisa M. LaVange, Philip Lavori, Andrew W. Lo, Alexander J. London, Victoria Manax, Colin McArthur, Genevieve O’Neill, Giovanni Parmigiani, Jane Perlmutter, Elizabeth A. Petzold, Craig Ritchie, Kathryn M. Rowan, Christopher W. Seymour, Nathan I. Shapiro, Diane M. Simeone, Bradley Smith, Bradley Spellberg, Ariel Dora Stern, Lorenzo Trippa, Mark Trusheim, Kert Viele, Patrick Y. Wen, and Janet Woodcock. "Adaptive Platform Trials: Definition, Design, Conduct and Reporting Considerations." Nature Reviews: Drug Discovery 18, no. 10 (October 2019): 797–807.
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at... View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
Linda A. Hill
Linda A. Hill is the Wallace Brett Donham Professor of Business Administration at the Harvard Business School and Faculty Chair of the Leadership Initiative. Hill is regarded as one of the top experts on leadership and innovation. Hill is... View Details
- Web
Capstone | MBA
that will advance new drug discoveries and therapeutics with those equally passionate about changing the business of healthcare for the better. 2. The practicalities of business decisions meet the practicalities of hard science. Students... View Details
- Web
Faculty & Advisors | MBA
Therapeutics (acquired by Vertex Pharmaceuticals), Korro Bio, Akouos (NASDAQ: AKUS), Gemini Therapeutics (NASDAQ: GMTX), Inipharm, and PACT Pharma. She was previously an investment professional at 5AM... View Details
- Web
Overview | MBA
relevant timeframes, opportunity-costs, rewards, and organizational behavior. Assess the potential therapeutic value of discoveries emanating from lab-discovery in the life sciences and understand ways to accelerate these discoveries into... View Details
- Web
Curriculum | MBA
FALL TERM Entrepreneurship in the Life Sciences Frontiers in Therapeutics Science Elective (2) HBS Electives Harvard Business School Life Science, Ethics, and Management Seminar January Capstone Project 1 SPRING Capstone Project 2 (2) HBS... View Details
- 01 Nov 2013
- HBS Seminar
Eric Olson, Chief Scientific Officer at Syros Pharmaceuticals
- 12 Jul 2016
- First Look
July 12, 2016
spending. Whereas traditional (small-molecule) drugs have historically faced price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already... View Details
Keywords: Sean Silverthorne
- Web
Hiring Organizations
Hydration Curio Digital Therapeutics Inc. Custom Truck One Source Cyprium Partners D D. E. Shaw Group, The Danone Databricks Datadog David Protein DaVita DC Advisory De Soi Decarbonization Partners DECKED Deloitte Delta Air Lines Diageo... View Details
- 11 Oct 2011
- Working Paper Summaries
US Healthcare Reform and the Pharmaceutical Industry
- May 2024
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
By: Caroline Marra and Ariel D. Stern
Digital health technologies (DHTs) can enable more patient-centric therapeutic development by generating evidence that captures how patients feel and function, enabling decentralized trial designs that increase participant inclusivity and convenience, and collecting... View Details
Keywords: Health Care and Treatment; Technological Innovation; Product Development; Health Testing and Trials; Governing Rules, Regulations, and Reforms
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics 115, no. 5 (May 2024): 988–992.
- Web
Blavatnik Fellowship in Life Science Entrepreneurship - Health Care
KiraGen Bio to create substantial value for all stakeholders. Stephen Linderman MD, PhD 2019 Stephen Linderman is the CEO and co-founder of Absco Therapeutics (AbscoTx), an immune oncology company specializing in image-guided,... View Details
- 01 Dec 2023
- News
Wide Horizon
There were three critical events that led John Rodakis (MBA 1997) to form the nonprofit N of One in 2014 and ultimately dedicate his life to surfacing breakthrough autism research. The first occurred on Thanksgiving of 2012. He had driven about four hours with his wife... View Details
Keywords: Dan Morrell; Photos by Sarah Wilson
- Web
Profiles - MBA
Intelligence, Biotechnology, and Cognitive Science. Formative experience at the intersection of technology and business: I caught the innovation bug during my time in San Diego working on a GABA(A) PAM pipeline for a CNS therapeutics... View Details